Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$301.94 USD

301.94
2,316,263

+5.06 (1.70%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $302.01 +0.07 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Sanghamitra Saha headshot

Can Dogs of the Dow ETFs Snap Losing Trend in 2024?

by Sanghamitra Saha

The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year?

Zacks Equity Research

Amgen (AMGN) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Zacks Equity Research

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

by Zacks Equity Research

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

Zacks Equity Research

Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Amgen (AMGN) reachead $273.99 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.

Zacks Equity Research

Here's Why Amgen (AMGN) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Equity Research

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.

Zacks Equity Research

3 Top Dividend Stocks to Maximize Your Retirement Income

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Zacks Equity Research

Pfizer (PFE) Stock Down 5% as Obesity Drug Fails in Phase II

by Zacks Equity Research

The failure of the phase IIb study on danuglipron is a significant blow to Pfizer's (PFE) efforts to take a share of the growing market of GLP-1 drugs for treating obesity.

Zacks Equity Research

Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report?

by Zacks Equity Research

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

The Zacks Analyst Blog Highlights McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software

by Zacks Equity Research

McDonald's, Amgen, NextEra Energy, General Mills and Take-Two Interactive Software are included in this Analyst Blog.

Zacks Equity Research

Amazon (AMZN) Teams Up With Amgen, Expands Customer Base

by Zacks Equity Research

Amazon's (AMZN) AWS gets selected by Amgen. This highlights the efficiency and reliability of AWS' innovative cloud products and services.

Sheraz Mian headshot

Top Stock Reports for McDonald's, Amgen & NextEra Energy

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Amgen Inc. (AMGN) and NextEra Energy, Inc. (NEE).

Zacks Equity Research

Is Trending Stock Amgen Inc. (AMGN) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Zacks Equity Research

Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHD

Zacks Equity Research

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.